Abstract:Currently, the treatment of gliomas still relies primarily on surgery and radiochemotherapy. Although there are various drugs available, including temozolomide, the overall therapeutic effect is unsatisfactory, and the prognosis remains poor. Therefore, the in-depth study of the mechanism of glioma development and a search for new therapeutic targets are the keys to improving the therapeutic treatment of gliomas and improving the prognosis of patients. Immunohistochemistry is used to detect the expression of relevant molecules in tissues, qPCR and Western blot are used to detect the mRNA and protein expression of relevant molecules, CCK-8 (Cell Counting Kit-8) is used to assess cell viability and proliferation capacity, Transwell is used to evaluate cell migration and invasion ability, and RNA transcriptome sequencing is used to identify the most influential pathways. SRPK1 (SRSF protein kinase 1) is highly expressed in gliomas but is not expressed in normal tissues. Its expression is positively correlated with the grades of gliomas and negatively correlated with prognosis. SRPK1 significantly promotes the occurrence and development of gliomas. Knocking down SRPK1 leads to a significant decrease in the proliferation, migration, and invasion abilities of gliomas. Loss of SRPK1 expression induces G2/M phase arrest and mitotic catastrophe, leading to apoptosis in cells. Overexpression of SRPK1 activates the Wnt/β-catenin (wingless-int1/β-catenin) and JAK-2/STAT-3 (Janus kinase 2/signal transducer and activator of transcription 3) signaling pathways, promoting the proliferation, migration, and invasion of gliomas. Overexpression of SRPK1 rescues the reduced cell proliferation, migration, and invasion abilities caused by the silencing of β-catenin or JAK-2. A stable shRNA-LN229 cell line was constructed, and using a nude mouse model, it was found that stable knockout of SRPK1 significantly reduced the tumorigenic ability of glioma cells, as evidenced by a significant decrease in the subcutaneous tumor volume and weight in nude mice. We have demonstrated that SRPK1 is highly expressed in gliomas. Overexpression of SRPK1 activates the Wnt/β-catenin and JAK-2/STAT-3 signaling pathways, promoting the proliferation, migration, and invasion of gliomas. Silencing SRPK1-related signaling pathways may provide potential therapeutic options for glioma patients.

Nur77 knock-down suppresses glioma by regulating CXCR4

Chemokine Receptor CXCR4 Interacts with Nuclear Receptor Nur77 and Promote Glioma Invasion and Progression.

Knockdown of Nupr1 Inhibits the Proliferation of Glioblastoma Cells Via Erk1/2, P38 Mapk and Caspase-3

Knockdown of NUPR 1 inhibits the proliferation of U 87 cells in vivo and vitro

Downregulation of Nuclear Protein-1 Induces Cell Cycle Arrest in G0/G1 Phase in Glioma Cells in Vivo and in Vitro Via P27

Hederagenin Suppresses Glioma Cell Biological Activities Via Nur77 in Vitro Study

Nur77-IRF1 axis inhibits esophageal squamous cell carcinoma growth and improves anti-PD-1 treatment efficacy

Knockdown of NF-E2-related Factor 2 Inhibits the Proliferation and Growth of U251MG Human Glioma Cells in a Mouse Xenograft Model

NUP37 promotes the proliferation and invasion of glioma cells through DNMT1-mediated methylation

SRPK1 Promotes Glioma Proliferation, Migration, and Invasion through Activation of Wnt/β-Catenin and JAK-2/STAT-3 Signaling Pathways

NRBP1 promotes malignant phenotypes of glioblastoma by regulating PI3K/Akt activation

Nur77 is a promoting factor in traumatic brain injury-induced nerve cell apoptosis.

Retraction Note To: Nuclear Protein C23 on the Cell Surface Plays an Important Role in Activation of CXCR4 Signaling in Glioblastoma

Inhibition of Gpr137 Expression Reduces the Proliferation and Colony Formation of Malignant Glioma Cells

Nur77 Inhibition of 13-Catenin Expression Mediates Hepatoblastoma Progression and Enhances Cisplatin's Therapeutic Effect

Downregulation of Gankyrin/PSMD10 affects cancer cell growth and proliferation in glioblastoma: in vitro and in vivo study

Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect

CircNUP98 promotes the malignant behavior of glioma cells through the miR‐520f‐3p/ELK4 axis

Pten Restoration and Pik3cb Knockdown Synergistically Suppress Glioblastoma Growth in Vitro and in Xenografts

NPS ‐2143 inhibit glioma progression by suppressing autophagy through mediating AKT–mTOR pathway

Curcumin suppresses glioblastoma cell proliferation by p-AKT/mTOR pathway and increases the PTEN expression